Monday, March 30, 2026

Surgical ablation reduces POAF but increases pacemaker risk in non-mitral valve surgery

Key Takeaway
Consider the trade-off between POAF reduction and pacemaker risk when adding surgical ablation to non-mitral valve procedures.

This systematic review and meta-analysis compared concomitant surgical ablation to isolated non-mitral valve surgery in patients with atrial fibrillation. The analysis included 2 randomized controlled trials and 5 propensity score-matched studies, encompassing a total of 39,348 AF patients undergoing non-mitral valve surgery. Of these patients, 18,394 (46.7%) underwent surgical ablation. The primary outcomes assessed were postoperative atrial fibrillation, early all-cause mortality, postoperative pacemaker implantation, and postoperative stroke. Risk ratios with 95% confidence intervals were calculated using a random effects model. Compared with isolated non-mitral valve surgery, surgical ablation was associated with a significant reduction in postoperative AF (RR: 0.73; 95% CI: 0.67 to 0.79; I²=0%). However, surgical ablation was also associated with a higher risk of postoperative pacemaker implantation (RR: 1.34; 95% CI: 1.14 to 1.57; I²=0%). No statistically significant differences were found between groups for early all-cause mortality (RR: 0.96; 95% CI: 0.76 to 1.22; I²=65%) or postoperative stroke (RR: 1.06; 95% CI: 0.89 to 1.26; I²=0%). A subgroup analysis comparing results from randomized controlled trials and propensity score-matched studies showed significant consistency across study designs. The authors concluded that while surgical ablation reduces postoperative AF in non-mitral valve surgery, it carries an increased risk of requiring postoperative pacemaker implantation, with no observed difference in early mortality or stroke.

View Original Abstract ↓
BACKGROUND: Surgical ablation (SA) is a key treatment for atrial fibrillation (AF) patients undergoing heart surgery. However, direct comparisons between SA and non-mitral valve (non-MV) surgery alone are lacking. We performed a systematic review and meta-analysis comparing concomitant SA to isolated non-MV surgery in AF patients. METHODS: MEDLINE, Embase and Cochrane were searched. Outcomes of interest were: (1) postoperative AF (POAF); (2) early all-cause mortality; (3) postoperative pacemaker implantation and (4) stroke. Additionally, a subgroup analysis comparing randomised controlled trials (RCTs) and propensity score-matched studies (PSM) was conducted. Risk ratios (RRs) and their respective 95% CI were calculated using a random effects model. RESULTS: After screening 6423 citations, we included 2 RCTs and 5 PSM studies encompassing 39 348 AF patients undergoing non-MV surgery, of whom 18 394 (46.7%) underwent SA. Compared with isolated non-MV surgery, SA was associated with significant POAF reduction (RR: 0.73; 95% CI: 0.67 to 0.79; I=0%) and higher risk of postoperative pacemaker implantation (RR: 1.34; 95% CI: 1.14 to 1.57, I=0%) compared with surgery alone. No differences were found in early all-cause mortality (RR: 0.96; 95% CI: 0.76 to 1.22; I=65%) and postoperative stroke (RR: 1.06; 95% CI: 0.89 to 1.26; I=0%). The subgroup analysis comparing RCTs and PSM showed significant consistency among the different designs. CONCLUSIONS: In this meta-analysis, SA was associated with POAF reduction in non-MV surgery. In terms of safety, it was suggested that although no difference in early mortality and postoperative stroke was observed, SA had a higher risk of pacemaker implantation than isolated non-MV surgery.